Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Shares of Q32 Bio were touching all-time lows in the after-hours market following results from a pair of Phase 2a clinical trials of the company's alopecia treatment bempikibart.

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which ...

Oppenheimer slashed its price target on the stock to $20 from $80, but maintained the stock at Outperform. This comes after ...

Leerink downgraded Q32 Bio (QTTB) to Market Perform from Outperform with a price target of $9, down from $68, following disappointing results ...

Shares of Q32 Bio (QTTB) plummeted over 60% in premarket trading Wednesday following mixed results from Phase 2a trials of ...

In a notable market movement, QTTB has reached a 52-week high, with its price soaring to $36.31. This significant milestone reflects a robust performance by the stock over the past... In a notable ...

Bempikibart is under clinical development by Q32 Bio Operations and currently in Phase II for Alopecia Areata. According to GlobalData,... Likelihood of Approval and Phase Transition Success Rate ...

Bempikibart is a monoclonal antibody commercialized by Q32 Bio, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).